Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

12.85
-0.8200-6.00%
Post-market: 12.850.00000.00%18:33 EDT
Volume:607.68K
Turnover:7.97M
Market Cap:777.76M
PE:-3.45
High:13.78
Open:13.57
Low:12.79
Close:13.67
52wk High:16.74
52wk Low:5.68
Shares:60.53M
Float Shares:43.02M
Volume Ratio:0.50
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7236
EPS(LYR):-3.7236
ROE:-44.02%
ROA:-28.22%
PB:1.90
PE(LYR):-3.45

Loading ...

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Disposes of Common Shares

Reuters
·
Feb 24

Cullinan Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

Reuters
·
Feb 23

Cullinan Therapeutics Joins Citi Virtual Oncology Leadership Summit Fireside Chat

Reuters
·
Feb 18

Cullinan Therapeutics Initiated at Buy by Citigroup

Dow Jones
·
Feb 17

Citigroup Initiates Cullinan Therapeutics at Buy With $33 Price Target

MT Newswires Live
·
Feb 17

Cullinan Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $33

THOMSON REUTERS
·
Feb 17

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

Reuters
·
Feb 10

Cullinan Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Feb 02

Guggenheim Initiates Coverage on Cullinan Therapeutics With Buy Rating, $30 Price Target

MT Newswires Live
·
Feb 02

Cullinan Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Feb 02

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Sale of Common Shares

Reuters
·
Jan 24

Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jan 23

Cullinan: Buy Rating Reiterated on 2026 Clinical Catalysts and Undervalued Pipeline Upside

TIPRANKS
·
Jan 09

Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 09

Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright

TIPRANKS
·
Jan 08

Cullinan Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $27 From $26

THOMSON REUTERS
·
Jan 08

Cullinan Therapeutics provides corporate update, anticipated 2026 milestones

TIPRANKS
·
Jan 08

Cullinan Therapeutics Reports $439 Million Cash Position and Previews 2026 Milestones

Reuters
·
Jan 08

Cullinan Therapeutics Inc - Zipalertinib Nda Submission Complete in Q1 2026

THOMSON REUTERS
·
Jan 08

Cullinan Therapeutics Inc - Expects Its Cash Resources to Provide Runway Into 2029 Under Its Current Operating Plan

THOMSON REUTERS
·
Jan 08